本文来源:时代财经 作者:张羽岐图片来源:视觉中国辉瑞(PFE.US)在减重赛道又开一局。美国当地时间9月22日,辉瑞在官网披露,其已与一家专注于肥胖症和心脏代谢疾病治疗的临床阶段生物制药公司Metsera(MTSR.US)达成收购协议,拟定收购方案将为辉瑞公司的产品线增添四个高度差异化的临床阶段肠促胰岛素和胰淀素项目,交易总价值高达73亿美元,交易预计于2025年第四季度完成。根据协议条款,辉瑞...
Source Link本文来源:时代财经 作者:张羽岐图片来源:视觉中国辉瑞(PFE.US)在减重赛道又开一局。美国当地时间9月22日,辉瑞在官网披露,其已与一家专注于肥胖症和心脏代谢疾病治疗的临床阶段生物制药公司Metsera(MTSR.US)达成收购协议,拟定收购方案将为辉瑞公司的产品线增添四个高度差异化的临床阶段肠促胰岛素和胰淀素项目,交易总价值高达73亿美元,交易预计于2025年第四季度完成。根据协议条款,辉瑞...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.